title: Clinical trial of droperidol for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
abstract: In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured using Haase's graphopathological test) and the maximum dose were determined. The neuroleptic threshold dose was 18.5 mg/day (SD = 8.84), the maximum dose was 38.2 mg/day (SD = 4.6). With reference to the effectiveness good to very good results were obtained in 15 cases. Regarding side effects 10 patients complained of extrapyramidal disturbances. This was to be expected in view of the study design aiming at the determination of the maximum dose.
mesh_terms: D000328:Adult; D002697:Chloral Hydrate / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004329:Droperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D002697:Chloral Hydrate; D004329:Droperidol